Results

Merck & Co. Inc.

11/29/2021 | Press release | Distributed by Public on 11/29/2021 05:50

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma